Select Location
What is your delivery location?
We need your delivery location to continue browsing
Select Location
We need your delivery location to continue browsing
Prescription Required
Natco Pharma
30 tablet
Erlotinib Hydrochloride
Keep in cold place
Delivering To:
Overview
Erlonat 150mg tablet treats advanced non-small cell lung cancer that has spread to nearby areas. It is also given to manage pancreatic cancer as per a doctor's prescription. This tablet has its salt constituents called 'Erlotinib' that belong to the drug class of 'kinase inhibitors. It stops the working of the abnormal protein that leads to cancerous growth. Erlonat is not recommended for children below 18 years of age.
non-small cell lung cancer (NSCLC) and pancreatic cancer
Pancreatic cancer
Non-small cell lung cancer
Most of the side effects after taking the Erlonat 150mg tablet do not require any special medical attention and will slowly disappear with time. However, it is advised to consult your doctor if you experience these side effects persistently. Some of the side effects are discussed below:
Fever
Rash
Cough
Fatigue
Diarrhea
Hair loss Vomiting Bone pain
Constipation
Muscles pain
Appetite loss
Abdominal pain
Difficulty in breathing
Infection in the mouth and stomach
Erlonat 150mg tablet is a prescription-based anticancer drug that should be administered orally. It is advised to take this tablet after consulting your healthcare expert.
An anti-cancer drug is Erlonat 100mg Tablet. The surface of lung cancer cells expresses epidermal growth factor receptors (EGFR), which control the proliferation of the cells. This medication inhibits the EGFR-mediated cancer signaling pathways by binding the chemical messenger EGFR. In this way, it prevents the cancer cells from growing further.
Alcohol
consult your doctor
The interaction of alcohol with this drug is still unknown. It is advisable not to consume alcohol while taking Erlonat 150mg tablet. It is advised to consult your doctor for further information.
Pregnancy
consult your doctor
Erlonat 150mg tablet may be considered unsafe during pregnancy. Please consult your doctor in such a condition.
Breast Feeding
consult your doctor
Erlonat 150mg tablet is probably not safe if you're breastfeeding. Kindly consult your doctor.
Driving
unsafe
It is advisable not to drive or operate heavy machinery as you may feel dizzy after taking an Erlonat 150mg tablet.
Kidney
consult your doctor
Share your medical history with your healthcare expert in case of kidney disease before taking the Erlonat 150mg tablet.
Liver
safe if prescribed
Inform your doctor before starting Erlonat 150mg tablet if you have liver disease to avoid any serious side effects.
It is advised not to miss any scheduled dosage of Erlonat 150mg tablet. In case you miss a dose, consult your doctor immediately.
Don't overdose to compensate for the missed one. Contact your doctor or any healthcare provider and seek medical attention immediately in such cases.
Inform your doctor immediately if you see blood in your stools after taking Erlonat 150mg Tablet.
Taking Erlonat 150mg Tablet can make your skin sensitive. So wear high SPF sunscreen while going out or exposed to direct sun rays.
Diarrhea is the most common side effect after taking Erlonat 150mg Tablet. So, drink plenty of water and fluid to keep your body hydrated.
Erlonat 150mg Tablet is not considered to be safe for pregnant and breastfeeding women, as it may pass through the mother and harm the baby.
It is advised to use trusted methods of birth control and contraceptive pills to delay pregnancy while under treatment with Erlonat 150mg Tablet.
Do not take antacids medicine (Medicine lowers the stomach acid) with Erlonat 150mg Tablet, as it may interact with the tablet and can affect the action.
Erlonat 150mg Tablet is considered to be safe for diabetic patients. However, it is important to consult your doctor about doses before taking them.
After taking the last medication, the doctor recommends waiting at least one month before getting pregnant. Therefore, while taking the Erlonat 150mg tablet for treatment, avoid getting pregnant by using safe birth control techniques and contraceptive pills.
It is recommended that you continue taking Erlonat 150mg tablet until your doctor instructs you to do so, even if rashes are observed as a frequent side effect. Avoid direct sunlight and apply sunscreen with a high SPF.
Erlonat 150mg Tablet should be taken with or without food as your healthcare expert prescribes. It is advised to take this pill with water at once, do not chew, break, or crush it.
Erlonat 150mg Tablet belongs to the drug class of kinase inhibitors that inhibit the abnormal protein that signals the multiplication and growth of cancer cells. It is not a chemotherapy medicine.
Jiao, W., et al. (2021). Efficacy and tolerability of erlotinib 100 mg/d vs. gefitinib 250 mg/d in EGFR‑mutated advanced non‑small cell lung cancer (E100VG250): an open‑label, randomized, phase 2 study. Oncotarget, 12(10), pp.32-70.
Nishio, M., Seto, T., Reck, M., et al. (2025). Final survival outcomes with ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated EGFR‑mutated metastatic NSCLC: RELAY Japanese subset. JTO Clinical Research Reports, 6(6), 100819.
Nomura, A., et al. (2021). Efficacy of erlotinib and its effects on the quality of life of older patients with EGFR‑mutant non‑small cell lung cancer: A multicenter, dose‑modification phase II study. Geriatrics & Gerontology International, 21(3), pp. 881–886.
Smith, A., et al. (2025). Phase II trial of chemotherapy, cetuximab, and erlotinib in metastatic or recurrent head and neck squamous cell carcinoma. medRxiv. Zhao, Y., Zhang, L., Fang, W., Zhang, J., Zhang, Y., Hong, S., Ma, S., Zhou, C., Yang, J., Huang, J., Zhao, Y., & Zhang, L. (2020). Efficacy and tolerability of erlotinib 100 mg/day versus gefitinib 250 mg/day in EGFR‑mutated advanced non‑small cell lung cancer: A randomized phase II study. Journal of Thoracic Oncology.
Natco Pharma
Written By
Venika Choudhary
Medical Content Writer @ Magicine Pharma
I hold an M.Sc. in Microbiology and have a strong academic foundation in microbial sciences and applied biotechnology. I began my career with extensive hands-on research at CSIR laboratories, focusing on fungal enzyme production, studying fungal diversity in various ecosystems, and developing bio-pesticides as sustainable alternatives to chemical pesticides. This work deepened my understanding of fungal biology, bioactive compounds, and their pharmaceutical and agricultural applications. Transitioning from research, I now work as a medical content writer, where I combine my scientific expertise with a passion for clear and reliable healthcare communication. I apply my research background to create patient-friendly, compliant content for pharmaceutical companies and healthcare platforms, ensuring science is both trustworthy and accessible. Specializing in clear, accurate, and engaging content, I help patients make informed decisions and support pharmaceutical companies in delivering trusted information. Whether writing product descriptions, crafting disease awareness articles, or composing drug information leaflets, I consistently meet regulatory standards and address audience needs, making my content an asset for healthcare brands.